ArticleUltrasonography (Seoul, Korea)2026
Effect of prophylactic platelet transfusion on bleeding risk in patients with cirrhosis and thrombocytopenia undergoing ultrasound-guided liver biopsy.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe utility of platelet transfusion for preventing post-biopsy bleeding in patients with cirrhosis and thrombocytopenia remains a topic of debate. This study investigated whether prophylactic transfusion reduces this risk.
methodsThis retrospective study included patients with cirrhosis and thrombocytopenia who underwent ultrasound-guided percutaneous liver biopsy (March 2018-October 2024) at a tertiary institution. Bleeding events were defined as major (requiring intervention or resulting in death) or minor (non-interventional hematoma). Pre- and post-transfusion platelet counts were compared, and bleeding incidence was examined by transfusion status. Logistic regression was used to identify factors associated with bleeding events. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were applied to assess bleeding incidence by transfusion status.
resultsThis study analyzed 526 biopsies from 497 patients (mean age, 62.1±10.6 years; 365 men [73.4%]), of whom 42 (8.0%) received prophylactic platelet transfusion. While platelet counts increased after transfusion (from 54.5×109/L to 72.5×109/L, P<0.001), no significant difference was observed in bleeding incidence between the transfused and non-transfused groups (31.0% vs. 20.9%, P=0.128). Multivariate analysis indicated that platelet transfusion was not associated with all bleeding (odds ratio [OR], 1.318; P=0.449) or major bleeding (OR, 1.754; P=0.420). PSM and IPTW analyses similarly revealed no association between transfusion and all bleeding (PSM: OR, 1.173; P=0.739; IPTW: OR, 0.907; P=0.807) or major bleeding (PSM: OR, 0.658, P=0.716; IPTW: OR, 0.863; P=0.876).
conclusionProphylactic platelet transfusion may not provide a universal benefit in patients with cirrhosis and thrombocytopenia, warranting a more tailored approach based on individual risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.